Aquestive Therapeutics Inc
NASDAQ:AQST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
US |
|
N
|
NCR Corp
LSE:0K45
|
US |
|
R
|
Roche Holding AG
SWB:RHO6
|
CH |
|
Nestle SA
SIX:NESN
|
CH |
|
M
|
Mehai Technology Ltd
BSE:540730
|
IN |
|
M
|
Microsoft Corp
MIL:MSFT
|
US |
|
R
|
Rheinmetall AG
XHAM:RHM
|
DE |
|
A
|
AMR Asia PCL
SET:AMR
|
TH |
|
M
|
Manulife Financial Corp
F:MLU
|
CA |
|
Beeks Financial Cloud Group PLC
LSE:BKS
|
UK |
|
A
|
American States Water Co
SWB:FDK
|
US |
|
Exxaro Resources Ltd
OTC:EXXAF
|
ZA |
|
LiveOne Inc
F:3510
|
US |
|
U
|
UniCredit SpA
LSE:0RLS
|
IT |
Wall St Price Targets
AQST Price Targets Summary
Aquestive Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AQST is 9.0667 USD with a low forecast of 6.06 USD and a high forecast of 11.55 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AQST's stock price target?
Price Target
9.0667
USD
According to Wall Street analysts, the average 1-year price target for AQST is 9.0667 USD with a low forecast of 6.06 USD and a high forecast of 11.55 USD.
What is the Revenue forecast for Aquestive Therapeutics Inc?
Projected CAGR
39%
Over the last 8 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 8 years is 39%.
What is the Gross Profit forecast for Aquestive Therapeutics Inc?
Projected CAGR
54%
Over the last 8 years, the compound annual growth rate for Gross Profit has been -7%. The projected CAGR for the next 4 years is 54%.